| Business Summary | | Matrix
Pharmaceutical,
Inc.
develops
and
manufactures
novel
drug
product
candidates
for
cancer
based
on
its
internal
research
and
development
capabilities
and
through
in-licensing
of
product
candidates
from
research
institutions
or
other
pharmaceutical
companies.
The
Company's
novel
pharmaceutical
product
candidates
are
designed
to
improve
the
delivery
of
cancer
drugs
for
more
effective
treatment
of
solid
tumors.
Two
product
candidates
of
the
Company
have
been,
or
are
being,
evaluated
in
human
clinical
trials.
These
are
IntraDose
(cisplatin/epinephrine)
Injectable
Gel
and
MPI
5020
Radiopotentiator.
The
Company
also
in-licenses
product
candidates
for
development.
In-licensed
in
1998,
tezacitabine
(FMdC)
is
an
intravenously
administered
therapeutic
being
developed
for
colorectal,
hematologic
and
other
cancers.
The
Company
currently
owns
worldwide
marketing
rights
for
all
its
products
under
development,
except
for
tezacitabine
in
Japan. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | MATX
is
a
development
stage
company
engaged
in
the
formulation
and
development
of
novel
pharmaceutical
product
candidates
that
are
designed
to
improve
the
delivery
of
cancer
drugs
to
more
effectively
treat
solid
tumors.
For
the
six
months
ended
6/30/01,
revenues
rose
66%
to
$715
thousand.
Net
loss
increased
31%
to
$14.7
million.
Revenues
reflect
an
increased
customer
base.
Net
loss
reflects
increased
S/G/A
expenses
due
to
higher
marketing
personnel
costs. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Michael Casey, 55 Chairman,
Pres and CEO | $711K | -- | Richard Leavitt, M.D., 55 Sr.
VP of Medical Affairs | 315K | $464K | Jeffrey Cooper, 45 VP-Fin. | -- | -- | Ronald Lucas, 58 VP,
Operations | 252K | 31K | Jeanette Fritzky, 46 VP
of Sales and Marketing | -- | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|